ChemPartner Boston Center of Excellence: Translational Discovery, In Vivo Pharmacology & DMPK Hub.
A dedicated R&D hub in the heart of the Boston-Cambridge life science corridor — built to bring ChemPartner’s global discovery and development engine closer to local biotech and pharma teams, with fast study design, close project interaction, and efficient handoff into our broader global network.
A local hub for global discovery
ChemPartner’s Boston Center of Excellence is a dedicated R&D hub designed to connect Boston-area biotech and pharma teams directly to ChemPartner’s global CRO network. Located in the heart of the Boston-Cambridge life science corridor, the center supports fast study design, close project interaction, and efficient handoff into broader biology, pharmacology, DMPK, and development capabilities across the ChemPartner organization.
From translational biology and in vivo pharmacology to DMPK and bioanalytical support, our Boston scientists work side by side with client teams to define the right experiments, generate decision-quality data, and connect local studies to a broader global development platform.
Built for fast, translational decisions
The Boston team focuses on the critical translational questions that shape program strategy:
We support the studies that shape early development strategy — from translational biology and in vivo pharmacology to DMPK and bioanalytical support — and connect each one to ChemPartner’s broader global platform.
In Vivo Pharmacology
Oncology and immuno-oncology efficacy studies with integrated PK, PD and biomarker readouts.
Translational Biology & MOA
Translational biology support and mechanism-of-action studies that clarify target engagement and pathway modulation.
DMPK & Bioanalysis
DMPK and bioanalytical method development for discovery and early development, closely aligned with pharmacology.
PK/PD Strategy & Leadership
PK/PD strategy and study design with biomarker integration, plus local scientific project leadership and program management.
Each engagement is led by experienced scientists who work directly with your team to define objectives, select the right models, and design studies that fit your development stage and risk profile.
Single-cell antibody discovery with the Beacon platform
For biologics and antibody discovery programs, ChemPartner’s Beacon platform adds a powerful single-cell capability to accelerate hit discovery and characterization. By screening thousands of plasma B cells in parallel — combining binding and functional readouts — the platform identifies high-value antibody candidates faster than traditional workflows and supports efficient downstream sequencing and characterization.
It connects naturally to ChemPartner’s broader biologics discovery capabilities for engineering, developability and downstream optimization.
Model selection guided by your mechanism
Our team partners with you to select and refine in vivo models that align with your target biology, modality and clinical strategy — emphasizing mechanistic insight, so studies clarify exposure, target engagement and pathway modulation, not just efficacy.
Oncology and immuno-oncology focus
- Efficacy studies in relevant tumor models
- Integration of PK, PD and biomarker readouts
- Optimization of dose, route and schedule to support anticipated clinical regimens
When appropriate, Boston-based studies can expand through ChemPartner’s larger in vivo network to increase cohort size, add endpoints, or evaluate more complex combinations.
Early PK to de-risk your program
We provide DMPK support designed to quickly answer key questions about your candidate’s behavior in vivo:
- Fit-for-purpose PK studies to guide dose selection
- Initial exposure and clearance assessments
- Input on formulation, route and frequency based on PK profiles
These studies help refine your pharmacology designs and prioritize the most promising candidates before committing to larger work.
Local bioanalysis and method development
- Development and qualification of assays to measure drug levels and key metabolites
- Sample analysis for PK and pharmacology studies
- Data interpretation in the context of PD and efficacy outcomes
With DMPK and bioanalysis closely aligned with in vivo pharmacology, we shorten feedback loops and enable faster, more integrated decision-making.
From Boston studies to global IND-enabling
Studies initiated at the Boston Center of Excellence are designed with downstream development in mind. Data, methods and study designs transfer directly into ChemPartner’s global network to support:
- Extended in vivo pharmacology and safety studies
- Expanded DMPK and bioanalytical characterization
- CMC and IND-enabling activities for small molecules and biologics
This reduces friction between discovery, translational work and development — helping you keep momentum as programs advance toward the clinic.
One team across sites
Your Boston-based project lead acts as a single point of contact, coordinating work across sites and functions. You gain the benefits of local collaboration plus the scale and depth of a global CRO/CDMO — without the complexity of managing multiple vendors.
Designed for face-to-face science
We built the Boston Center of Excellence to support highly interactive partnerships, including:
- On-site working sessions and protocol design workshops
- Joint data reviews and decision meetings with your project team
- Scientific advisory input on model selection, study sequencing and development strategy
With local presence, it is easy to iterate on study design, adjust to new data, and keep programs aligned with your evolving strategic goals.
Flexible engagement models
We support a range of engagement models, from one-off studies to fully integrated, multi-program collaborations. Whether you are a seed-stage biotech needing rapid proof-of-biology or an established pharma team looking to extend your internal capacity, our Boston team can tailor scope, timelines and communication cadence to fit how you work.
Frequently Asked Questions — ChemPartner Boston
What is ChemPartner’s Boston Center of Excellence?
A dedicated R&D hub in the Boston-Cambridge life science corridor that brings ChemPartner’s global discovery and development engine closer to local biotech and pharma teams. It focuses on translational biology, in vivo pharmacology and DMPK, with fast study design, close project interaction, and efficient handoff into ChemPartner’s broader global capabilities.
What can I run at the Boston site?
In vivo pharmacology in oncology and immuno-oncology models, translational biology support and mechanism-of-action studies, DMPK and bioanalytical method development, PK/PD strategy and study design, Beacon single-cell antibody discovery, and local scientific project leadership.
How does the Beacon platform accelerate antibody discovery?
It screens thousands of plasma B cells in parallel at single-cell resolution, combining binding and functional readouts to identify high-value antibody candidates faster than traditional workflows, then supports efficient downstream sequencing and characterization.
How does Boston connect to ChemPartner’s global network?
Studies initiated in Boston are designed for downstream development. Data, methods and study designs transfer directly into ChemPartner’s global network to support extended in vivo pharmacology and safety, expanded DMPK and bioanalysis, and CMC and IND-enabling work — so you can start locally and scale without managing multiple vendors.
What engagement models does the Boston team offer?
Everything from one-off studies to fully integrated, multi-program collaborations. Whether you are a seed-stage biotech needing rapid proof-of-biology or an established pharma team extending internal capacity, the Boston team tailors scope, timelines and communication cadence, with a local project lead as your single point of contact.
Start the Conversation
Let’s design the right studies for your program. Talk with our Boston scientific team about model selection, PK/PD strategy, antibody discovery, or a fully integrated, multi-program collaboration.